Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
Author:
Publisher
Elsevier BV
Subject
General Pharmacology, Toxicology and Pharmaceutics
Reference131 articles.
1. Considerations for the design of antibody-based therapeutics;Goulet;J Pharmaceut Sci,2020
2. Muromonab-CD3 (orthoclone OKT3): the first monoclonal antibody approved for therapeutic use;Emmons;Iowa Med,1987
3. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the herceptin adjuvant (HERA) trial;Cameron;Lancet,2017
4. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience;Salles;Adv Ther,2017
5. Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies;Torka;Curr Hematol Malig Rep,2019
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges;Molecular Biotechnology;2024-09-02
2. Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment;Drug Discovery Today;2024-09
3. Investigation on environmental factors contributing to bispecific antibody stability and the reversal of self-associated aggregates;Bioresources and Bioprocessing;2024-08-23
4. Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors;Cancer Immunology, Immunotherapy;2024-08-06
5. Therapeutic potential of cis-targeting bispecific antibodies;Cell Chemical Biology;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3